Yes, I can understand why you have doubts. My understanding is that they are only filing for one dose of Rexista not more and is it including all of their technologies on abuse prevention and delivery system?
It appears to me, there are a lot more work to be done before Rexista II? I know IPCI have a lot in the pipeline, but at this point the company's worth is pretty much the two ANDA and one dose of Rexista version one that can be priced into the company value. Even with other ANDA approvals in the next 6 month, it isn't likely to add much value to the company. I think this is why the streets isn't pricing IPCI higher at the moment.
This is the reason I am more conservative. I don't have very high expectations for IPCI but I can see things changing in years to come. It will likely take longer than most expect for IPCI to get to that point.
News 
Market Data 
Discover 
AI
